Laurence Feldmeyer

Dr. Laurence Feldmeyer

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LFLaurence Feldmeyer
Laurence Feldmeyer
KHKristine Heidemeyer
Kristine Heidemeyer
NYNikhil Yawalkar
Nikhil Yawalkar
Acute generalized exanthematous pustulosis (AGEP) is a severe, usually drug-related reaction, characterized by an acute onset of mainly small non-follicular pustules on an erythematous base and spontaneous resolution usually within two weeks. Systemic involvement occurs in about 20% of cases. The course is mostly benign, and only in rare cases complications lead to life-threatening situations. Recent studies highlight the importance of genetic variations in interleukin-36 receptor antagonist gene (IL-36RN) in the pathogenesis of this disease. The physiopathology of AGEP remains unclear, but an involvement of innate and acquired immune cells together with resident cells (keratinocytes), which recruit and activate neutrophils via production of cytokines/chemokines such as IL-17, IL-36, granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor alpha (TNFα) and chemokine (C-X-C motif) ligand 8 (CXCL8)/IL-8, has been postulated. Treatment is based on the removal of the causative drug, supportive care, infection prevention and use of potent topical or systemic steroids.

15 May 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NGNicolas Gestermann
Nicolas Gestermann
JDJeremy Di Domizio
Jeremy Di Domizio
Roberto LandeRoberto Lande
Roberto Lande
ODOlivier Demaria
Olivier Demaria
Loredana FrascaLoredana Frasca
Loredana Frasca
MGMichel Gilliet
Michel Gilliet
Lupus erythematosus (LE) patients develop autoantibodies that form circulating immune complexes (ICs) with extracellular self-nucleic acids. These ICs are deposited into peripheral tissues, where they trigger detrimental organ inflammation. Recent evidence suggests that ICs contain LL37–DNA complexes derived from neutrophil extracellular traps (NETs) and that LE patients develop pathogenic autoantibodies against these structures, including Abs to LL37. However, the mechanism that leads to the generation of these Abs is unknown. In this study, we show that NETs directly trigger Ab production by human memory B cells. This occurs via LL37–DNA complexes present in NETs, which have the unique ability to gain access to endosomal compartments of B cells and to trigger TLR9 activation. In LE patients, NET-derived LL37–DNA complexes trigger polyclonal B cell activation via TLR9, but also specifically expand self-reactive memory B cells producing anti-LL37 Abs in an Ag-dependent manner. These findings suggest a unique link between neutrophils and B cells in which NETs trigger a concerted activation of TLR9 and BCR leading to anti-NET autoantibody production in lupus.

16 October 2024 in Nature
Verified
Journal Article
Open access
PDF file
TNThierry M. Nordmann
Thierry M. Nordmann
HAHolly Anderton
Holly Anderton
AHAkito Hasegawa
Akito Hasegawa
LSLisa Schweizer
Lisa Schweizer
PZPeng Zhang
Peng Zhang
MMMatthias Mann
Matthias Mann
Toxic epidermal necrolysis (TEN) is a fatal drug-induced skin reaction triggered by common medications and is an emerging public health issue1–3. Patients with TEN undergo severe and sudden epidermal detachment caused by keratinocyte cell death. Although molecular mechanisms that drive keratinocyte cell death have been proposed, the main drivers remain unknown, and there is no effective therapy for TEN4–6. Here, to systematically map molecular changes that are associated with TEN and identify potential druggable targets, we utilized deep visual proteomics, which provides single-cell-based, cell-type-resolution proteomics7,8. We analysed formalin-fixed, paraffin-embedded archived skin tissue biopsies of three types of cutaneous drug reactions with varying severity and quantified more than 5,000 proteins in keratinocytes and skin-infiltrating immune cells. This revealed a marked enrichment of type I and type II interferon signatures in the immune cell and keratinocyte compartment of patients with TEN, as well as phosphorylated STAT1 activation. Targeted inhibition with the pan-JAK inhibitor tofacitinib in vitro reduced keratinocyte-directed cytotoxicity. In vivo oral administration of tofacitinib, baricitinib or the JAK1-specific inhibitors abrocitinib or upadacitinib ameliorated clinical and histological disease severity in two distinct mouse models of TEN. Crucially, treatment with JAK inhibitors (JAKi) was safe and associated with rapid cutaneous re-epithelialization and recovery in seven patients with TEN. This study uncovers the JAK/STAT and interferon signalling pathways as key pathogenic drivers of TEN and demonstrates the potential of targeted JAKi as a curative therapy.

1 January 2010 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
LFLaurence Feldmeyer
Laurence Feldmeyer
CBC Benden
C Benden
SHSr Haile
Sr Haile
ABA Boehler
A Boehler
RSR Speich
R Speich
GHGfl Hofbauer
Gfl Hofbauer
Intravenous immunoglobulin (IVIG) is used for many indications beyond the original substitution in p...

5 December 2011 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
LFLaurence Feldmeyer
Laurence Feldmeyer
Günther F.L. HofbauerGünther F.L. Hofbauer
Günther F.L. Hofbauer
TBT. Böni
T. Böni
LFL.E. French
L.E. French
JHJ. Hafner
J. Hafner

30 September 2019 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
LFLaurence Feldmeyer
Laurence Feldmeyer
VSV.G. Suter
V.G. Suter
COC. Oeschger
C. Oeschger
SCSimone Cazzaniga
Simone Cazzaniga
MBM.M. Bornstein
M.M. Bornstein
Helmut BeltraminelliHelmut Beltraminelli
Helmut Beltraminelli